CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 183-185

  Rae, J M ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; DNA; DRUG METABOLIZING ENZYME; ENDOXIFEN; ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ALLELE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DRUG POTENCY; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MAPPING; GENETIC ASSOCIATION; GENOTYPE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; ESTROGEN ANTAGONISTS; FEMALE; GENOTYPE; HUMANS; POSTMENOPAUSE; TAMOXIFEN;

EID: 84880746919     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.102     Document Type: Review

References (11)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
2. Hertz, D.L., McLeod, H.L. & Irvin, W.J., Jr. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 17, 620-630 (2012).
3. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
4. Ratain, M.J., Nakamura, Y. & Cox, N.J. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin. Pharmacol. Ther. 94, 185-187 (2013).
5. Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
6. Regan, M.M. et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl. Cancer Inst. 104, 441-451 (2012).
7. Rae, J.M. et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl. Cancer Inst. 104, 452-460 (2012).
8. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007). (Pubitemid 350232249)
9. Nakamura, Y., Ratain, M.J., Cox, N.J., McLeod, H.L., Kroetz, D.L. & Flockhart, D.A. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrineresponsive breast cancer: The Breast International Group 1-98 Trial. J. Natl. Cancer Inst. 104, 1266-1268 (2012).
10. Castells, A., Gusella, J.F., Ramesh, V. & Rustgi, A.K. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res. 60, 2836-2839 (2000). (Pubitemid 30395802)
11. Koboldt, D.C. et al. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).